# Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

> **NCT01582776** · PHASE1,PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 317 (actual)

## Conditions studied

- Follicular Lymphoma Patients (Phase IB)
- Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

## Interventions

- **DRUG:** Lenalidomide and GA101

## Key facts

- **NCT ID:** NCT01582776
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-03
- **Primary completion:** 2018-07-11
- **Final completion:** 2022-05-20
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2023-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582776, "Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01582776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*